Login to Your Account



Other News To Note


Wednesday, January 26, 2011
Oxford BioTherapeutics, of Oxford, UK, said that Sanofi-Aventis SA, of Paris, acquired an exclusive worldwide license to one of OBT's internal preclinical antibody programs.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription